England Approves 1-Minute Injectable Pembrolizumab for 14,000 Cancer Patients
Updated
Updated · BioXconomy · May 22
England Approves 1-Minute Injectable Pembrolizumab for 14,000 Cancer Patients
2 articles · Updated · BioXconomy · May 22
Up to 14,000 patients in England will switch to an injectable form of pembrolizumab that can be given in one minute every three to six weeks.
The approval replaces intravenous dosing that requires sterilization procedures and takes several hours, sharply reducing treatment time for patients receiving the PD-1 immunotherapy.
Pembrolizumab is used across multiple cancers and works by binding to the PD-1 protein on T cells, helping the immune system recognize and attack cancer cells.
The decision adds to a run of antibody-therapy advances in the UK, including NICE backing for wider durvalumab use in gastric and gastroesophageal cancer after strong late-stage trial results.
Beyond survival rates, how will a one-minute injection truly change the daily lives of 14,000 cancer patients?
With new cancer drugs tied to specific biomarkers, what happens to patients who lack the right genetic profile?
Why do similar blockbuster immunotherapies show dramatically different results when treating the very same type of cancer?
Rapid Injectable Pembrolizumab Debuts in England: A Game-Changer for NHS Cancer Treatment Efficiency
Overview
In May 2026, NHS England introduced a rapid injectable form of pembrolizumab (Keytruda), marking a major shift in cancer treatment. This new subcutaneous injection, which helps the immune system attack cancer cells, replaces the traditional lengthy intravenous infusions with a quick and convenient shot. The change not only saves patients significant time in hospitals but also improves the efficiency of the healthcare system. As the world’s top-selling prescription medicine, pembrolizumab’s new delivery method promises more accessible, patient-centered care and sets the stage for further innovation in cancer therapy across England.